(Q30395583)

21 June 2017

title

An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers (English)

1 reference

21 June 2017

0 references

1 reference

1 reference

13

Rebecca J Cox

1 reference

21 June 2017

Abdullah S Madhun

1

1 reference

21 June 2017

Per Espen Akselsen

2

1 reference

21 June 2017

Haakon Sjursen

3

1 reference

21 June 2017

Gabriel Pedersen

4

1 reference

21 June 2017

Signe Svindland

5

1 reference

21 June 2017

Jane Kristin Nøstbakken

6

1 reference

21 June 2017

Mona Nilsen

7

1 reference

21 June 2017

Kristin Mohn

8

1 reference

21 June 2017

Asne Jul-Larsen

9

1 reference

21 June 2017

Ingrid Smith

10

1 reference

21 June 2017

Diane Major

11

1 reference

21 June 2017

John Wood

12

1 reference

21 June 2017

language of work or name

English

0 references

publication date

27 October 2010

1 reference

21 June 2017

1 reference

21 June 2017

volume

29

1 reference

21 June 2017

issue

2

1 reference

21 June 2017

page(s)

266-273

1 reference

Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Response to a monovalent 2009 influenza A (H1N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

A novel influenza A (H1N1) vaccine in various age groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Parenteral influenza vaccination induces a rapid systemic and local immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Reproducibility of serologic assays for influenza virus A (H5N1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

10.1016/J.VACCINE.2010.10.038

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference